ABC Arbitrage SA Invests $1.26 Million in Johnson & Johnson (NYSE:JNJ)

ABC Arbitrage SA bought a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 8,736 shares of the company's stock, valued at approximately $1,263,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. IFS Advisors LLC lifted its holdings in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after purchasing an additional 100 shares during the last quarter. Highline Wealth Partners LLC bought a new stake in shares of Johnson & Johnson in the third quarter valued at approximately $31,000. RPg Family Wealth Advisory LLC purchased a new stake in shares of Johnson & Johnson during the 3rd quarter valued at approximately $35,000. Bay Harbor Wealth Management LLC bought a new position in Johnson & Johnson in the 4th quarter worth approximately $32,000. Finally, Mowery & Schoenfeld Wealth Management LLC grew its stake in Johnson & Johnson by 58.7% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock valued at $40,000 after buying an additional 91 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of analyst reports. Wells Fargo & Company cut their price target on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a report on Thursday, January 23rd. Raymond James cut their target price on Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a research note on Thursday, January 23rd. Argus upgraded Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Stifel Nicolaus cut their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a research report on Thursday, January 23rd. Finally, Citigroup decreased their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a report on Wednesday, December 11th. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $170.67.

Remove Ads

Johnson & Johnson Price Performance

JNJ stock traded up $2.67 during mid-day trading on Friday, hitting $162.35. 12,540,171 shares of the stock were exchanged, compared to its average volume of 9,073,381. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a market capitalization of $390.87 billion, a price-to-earnings ratio of 24.41, a PEG ratio of 2.53 and a beta of 0.52. The business has a fifty day moving average price of $148.93 and a 200 day moving average price of $155.90. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Johnson & Johnson's revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.29 earnings per share. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.06%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson's payout ratio is presently 74.59%.

Insiders Place Their Bets

In related news, Director Mark A. Weinberger purchased 1,000 shares of the firm's stock in a transaction on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now directly owns 1,000 shares of the company's stock, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.